JPRN-UMIN000017634尚未招募2 期
The role of post-operative cetuximab-based bioradiotherapy in high risk head and neck carcinomas. - Post-operative bioradiotherapy in high risk head and neck carcinomas
Department of Otolaryngology- Head and Neck Surgery, Hokkaido University Graduate school of Medicine.0 个研究点目标入组 20 人开始时间: 2015年5月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The cases with a history of Interstitial pneumonia. The cases with a history of irradiation on head and neck region. The cases that researchers regard as inadequate.
研究者
相似试验
进行中（未招募）
不适用
Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck - RECETPreirradiated patients with locally recurrent or with secondary squamous cell carcinoma of the head and neckMedDRA version: 12.1Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckEUCTR2007-004280-22-DEniversitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie
已完成
2 期
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By SurgeryHead and Neck CancerNCT00738868Centre Oscar Lambret45
进行中（未招募）
1 期
Multimodal therapy (chemotherapy, radiation, surgery) with and without cetuximab, an additional anti-tumor agent, in patients with locally advanced esophageal carcinoma.MedDRA version: 20.0 Level: LLT Classification code 10056092 Term: Adenocarcinoma of oesophagus System Organ Class: 100000004864ocally advanced esophageal carcinoma.MedDRA version: 20.0 Level: LLT Classification code 10041824 Term: Squamous cell carcinoma of esophagus System Organ Class: 100000004864EUCTR2009-016584-10-DESchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300
进行中（未招募）
不适用
Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trialocally advanced esophageal carcinoma.EUCTR2009-016584-10-HUSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300
进行中（未招募）
1 期
Multimodal therapy (chemotherapy, radiation, surgery) with and without cetuximab, an additional anti-tumor agent, in patients with locally advanced esophageal carcinoma.ocally advanced esophageal carcinoma.MedDRA version: 20.0Level: LLTClassification code 10056092Term: Adenocarcinoma of oesophagusSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10041824Term: Squamous cell carcinoma of esophagusSystem Organ Class: 100000004864EUCTR2009-016584-10-ATSchweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK300